Skip to main content

and
  1. Article

    Open Access

    Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors

    Hypoxia is prominent in solid tumors and a recognized driver of malignancy. Thus far, targeting tumor hypoxia has remained unsuccessful. Myo-inositol trispyrophosphate (ITPP) is a re-oxygenating compound witho...

    Marcel A. Schneider, Michael Linecker, Ralph Fritsch in Nature Communications (2021)